Fig. 1: Manhattan plot of the genome-wide association analysis of maximum total bilirubin in sarilumab + DMARD-treated patients (N = 755) during the treatment periods.
The most significant variant was in the UGT1A1 gene (rs4148325; p = 2.88 × 10−41).
